Nigeria’s ratification of the African Medicines Agency (AMA) Treaty is more than a diplomatic milestone. It is an opportunity to strengthen public health protection, improve pharmaceutical regulation and reposition the country within Africa’s evolving health security framework. We believe the federal government should now ensure that this commitment produces measurable benefits for Nigerians.
By depositing its instrument of ratification as the 34th African Union member state, Nigeria has taken an important step towards a more coordinated continental system for regulating medicines and medical products. The treaty, which entered into force in November 2021, provides a framework for cooperation among national regulatory authorities and improved access to safe, effective and quality-assured medical products.
We see particular significance in Nigeria’s participation because of the country’s population size and position as one of Africa’s largest pharmaceutical markets. The circulation of substandard and falsified medicines remains a serious public health concern. Weak regulatory coordination, uneven enforcement and gaps in supply-chain oversight can expose citizens to unsafe products and undermine confidence in healthcare delivery.
We consider the AMA framework an opportunity for the federal government to strengthen the capacity of the National Agency for Food and Drug Administration and Control (NAFDAC), improve information sharing and deepen scientific cooperation with other African regulators. Harmonised standards could also reduce unnecessary regulatory barriers and make it easier for legitimate pharmaceutical manufacturers to access wider African markets. However, this will depend on effective implementation and mutual confidence among participating countries.
The economic implications deserve equal attention. Nigeria’s pharmaceutical industry requires an environment that encourages investment, innovation, technology transfer and local production. We believe stronger regulatory systems can support these objectives by improving product standards and investor confidence. Yet, regulatory cooperation alone cannot build a competitive pharmaceutical industry. Access to affordable financing, reliable energy, research infrastructure, skilled personnel and essential manufacturing inputs must also feature in the government’s strategy.
We therefore urge the federal government to translate ratification into a clear implementation programme. NAFDAC should receive the institutional support, technical resources and funding required to meet its expanded responsibilities. The Ministries of Health, Industry and Trade should also coordinate policies that connect medicines regulation with local manufacturing, research and pharmaceutical investment.
We also call for transparent performance measures covering regulatory capacity, the detection of falsified medicines, product safety monitoring, local production and access to affordable essential medicines. Such indicators would help Nigerians assess whether the treaty is improving public health outcomes rather than remaining a formal international commitment.
As NAFDAC Director-General, Professor Mojisola Adeyeye, has emphasised, the success of the AMA will depend on its ability to improve access to safe, effective, quality-assured and affordable medicines. We agree. Nigeria’s 34th-place ratification milestone should mark the beginning of sustained action, not the conclusion of the process.
Ultimately, we believe the federal government must treat the AMA Treaty as both a public health obligation and an economic development opportunity. Its value will be measured by safer medicines, stronger domestic pharmaceutical capacity and improved access for citizens.
